Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK/PD of HT-4253 in Healthy Adults
NCT06537817Phase 1Completed
- Sponsor
- Halia Therapeutics
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and Parkinson's disease (PD) comparing HT-4253 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple ascending doses up to 6 weeks. Started Sep 2024; status: completed.
02
Drugs
HT-4253
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06537817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537817.